CGRP mAb Subcutaneous denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for cgrp mab subcutaneous are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny Subcutaneous CGRP Monoclonal Antibodies as Experimental — and Why You Can Appeal

A denial coded as "experimental," "investigational," or "not medically necessary due to lack of sufficient evidence" for a subcutaneous CGRP monoclonal antibody is unusual given that multiple agents in this class hold full FDA approval for migraine prevention — but it does occur. It typically happens when the specific indication being treated (for example, a migraine subtype, a pediatric use, or a use outside the labeled population) does not match the exact approved labeling, or when Aetna's clinical policy has not yet been updated to reflect a newer FDA approval.

The key legal lever here is the distinction between FDA approval status and Aetna's internal evidence standard. Insurers must apply evidence criteria consistent with accepted clinical standards.

## Federal Appeal Framework

Experimental/investigational denials carry the same federal appeal rights as any other adverse benefit determination. ACA Section 2719 requires external review by an independent organization for non-grandfathered plans. ERISA Section 503 requires a full-and-fair review for employer-sponsored plans. File internally within approximately 180 days of the denial. If upheld, request external review within approximately four months. Expedited review is available when delay would seriously jeopardize your health.

Note: Federal mental-health parity law and state clinical-evidence standards may impose additional constraints on how Aetna defines "experimental" — worth raising in your appeal letter.

## Concrete Appeal Steps

1. Identify from the denial letter whether Aetna cited its internal clinical policy, a specific evidence standard, or the FDA approval status. 2. Obtain Aetna's published clinical policy for CGRP monoclonal antibodies and locate the evidence criteria language. 3. Confirm the FDA approval status of the specific agent prescribed — obtain this from the FDA prescribing label, not from secondary sources. 4. If the denial is based on an off-label use, your prescriber's letter should reference the applicable professional society guideline supporting that use.

## Documentation to Gather

• FDA-approved prescribing label: confirming the indication and population for which the drug is approved
• Prescriber medical-necessity letter: explaining why the prescribed use is supported by the current standard of care and citing the relevant guideline organization (e.g., American Headache Society, American Academy of Neurology)
• Diagnosis documentation: chart notes confirming the specific indication, migraine subtype, frequency, and severity
• Prior-treatment history: demonstrating that standard preventive approaches were tried and failed, establishing why this therapy is now appropriate

## Criteria-Mapping Structure

Copy each "experimental" criterion from Aetna's policy. For each criterion, enter the specific evidence that addresses it: FDA approval status of the drug for this indication, the professional society guideline supporting use, and your prescriber's clinical assessment. If the denial turns on an off-label use, document the body of evidence your prescriber is relying on, referencing the guideline organization rather than specific trial names or statistics.